Levosimendan for heart-operated patients: What is the state of the art?

Recent Patents on Cardiovascular Drug Discovery

Volumn 4, Issue 1, 2009, Pages 22-24

  Tagarakis, Georgis I ^a   Tsilimingas, Nikolaos B ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Acute heart failure; Inotropic agent; Levosimendan; Vasodilation and heart surgery

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; LEVOSIMENDAN; PLACEBO; SIMDAXA; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG STRUCTURE; DYSPNEA; FATIGUE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SURGERY; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; HYPOTENSION; INOTROPISM; MORBIDITY; MORTALITY; NAUSEA; PRIORITY JOURNAL; RISK REDUCTION; SUPRAVENTRICULAR TACHYCARDIA; HEART FAILURE; REVIEW;

CARDIAC SURGICAL PROCEDURES; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYDRAZONES; PYRIDAZINES;

EID: 65549129218     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489009787260052     Document Type: Article

References (21)

1. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98: 2141-2147.
2. Patel, J.: WO2008082871 (2008).
3. Slawsky MT, Colluci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators. Circulation 2000; 102: 2222-2227.
4. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000; 68: 522-531.
5. Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 1999; 274: 23932-23939.
6. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859-1866
7. Kopustinskiene DM, Pollesello P, Saris E. Levosimendan is a mitochondrial KATP channel opener. Eur J Pharmacol 2001; 428: 311-314.
8. Poder P, Eha J, Sundberg S, et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: A dosal interval study. J Clin Pharmacol 2004; 44: 1143-1150.
9. Antila S, Kivikko M, Lehtonen L, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 2004; 57: 412-415.
10. Rossi S, Ed, Australian Medicines Handbook 2008. Adelaide, Australian Medicines Handbook Pvt. Ltd. 2008.
11. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy, of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: A randomized, placebo-controlled, double blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432.
12. De Luca L, Colluci W, Nieminen M, Massie B, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006; 27(16): 1908-1920.
13. Delgado-Herrera, L., Padley, R.J., Salon, J.E., Thakkar, R.B., Huang, B.: US20080077025 (2008).
14. Folath F, Cleland JGF, Just H, et al. Efficacy and safety of levosimendan compare with dobutamine in severe low output heart failure (the LIDO study): A randomized, double blind trial. Lancet 2002; 360: 196-202.
15. Mebazaa A, Nieminen MS, Packer M, et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompansated heart failure: The SURVIVE randomized trial. JAMA 2007; 297: 1883-1891.
16. 2+ sensitizers after heart transplantation. Transplant Proc 2008; 40(4): 951-952.
17. 2+ sensitizer superior to catecholamine during myocardial stunning? Eur J Cardiothorac Surg 2008; 34(2): 326-331.
18. Joergensen K, Bech Hanssen O, Houltz E, Ricksten SE. Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis. Circulation 2008; 117: 1075-1081.
19. Lehmann A, Kiessling AH, Isgro F, Zeitler C, Thaler E, Boldt J. Levosimendan in patients with acute myocardial ischaemia undergoing emergency surgical revascularization. Eur J Anaesthesiol 2008; 25(3): 224-229.
20. Tasouli A, Papadopoulos K, Antoniou T, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: Importance of early use. Eur J Cardiothorac Surg 2007; 32(4): 629-633.
21. Nijhawan N, Nicolosi A, Montgomery MW, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo controlled trial. J Cardiovasc Pharmacol 1999; 34: 219-228.